Download PDF
Synlett 2009(3): 451-455  
DOI: 10.1055/s-0028-1087545
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis of Unnatural C-2 Amino Acid Nucleosides Using NIS-Mediated Ring Opening of 1,2-Cyclopropane Carboxylated Sugar Derivatives

Shrutisagar Dattatraya Haveli, Sudipta Roy, Srinivasan Chandrasekaran*
Department of Organic Chemistry, Indian Institute of Science, Bangalore 560012, India
e-Mail: scn@orgchem.iisc.ernet.in;
Further Information

Publication History

Received 2 October 2008
Publication Date:
21 January 2009 (online)

    Permissions and Reprints All articles of this category

Abstract

We have developed a general and efficient method for the stereoselective construction of pyrimidine-based pyranosyl C-2 amino acid nucleosides using NIS-mediated ring opening of 1,2-­cyclopropanated sugar derivatives. This methodology has been successfully extended to the synthesis of furanosyl nucleosides, which have potential applications in the development of novel, nontoxic antifungal therapeutics.

Key words

amino acid nucleoside - donor-acceptor - polyoxin - purine - pyrimidine

    References and Notes

  • 1 Isono K. J. Antibiotics  1988,  41:  1711 
    Google Scholar
  • 2 Isono K. Pharmacol. Ther.  1991,  52:  269 
    CrossrefGoogle Scholar
  • 3 Suhadolnik RJ. Nucleoside Antibiotics   Wiley; New York: 1970. 
    Google Scholar
  • For reviews, see:
  • 4a Zang D. Miller MJ. Curr. Pharm. Des.  1995,  5:  73 ; and references therein
    Google Scholar
  • 4b Garner P. Synthetic Approaches to Complex Nucleoside Antibiotics, In Studies in Natural Products Chemistry, Stereoselective Synthesis (Part A)   Vol. 1:  . Elsevier; Amsterdam: 1988.  p.397 
    Google Scholar
  • 4c Knapp S. Chem. Rev.  1995,  95:  1859 ; and references therein
    Google Scholar
  • 5a Aggarwal VK. Monteiro N. J. Chem. Soc., Perkin Trans. 1  1997,  2531 
    Google Scholar
  • 5b Poon KWC. Liang N. Datta A. Nucleosides Nucleotides  2008,  27:  389 
    Google Scholar
  • 6 Sridhar PR. Ashalu KC. Chandrasekaran S. Org. Lett.  2004,  6:  1777 
    CrossrefGoogle Scholar
  • 7 Haveli SD. Perumal S. Sridhar PR. Chandrasekaran S. Org. Lett.  2007,  9:  1331 
    CrossrefGoogle Scholar
  • 8 Timmers CM. Leeuwenburgh MA. Verheijen JC. Marel VG. Boom JH. Tetrahedron: Asymmetry  1996,  7:  49 
    CrossrefGoogle Scholar
  • 9 González-Díaz H. Bonet I. Terán C. De Clercq E. Bello R. García MM. Santana L. Uriarte E. Eur. J. Med. Chem.  2007,  42:  580 
    CrossrefGoogle Scholar
  • 12 Tian WQ. Wang YA. J. Org. Chem.  2004,  69:  4299 
    CrossrefGoogle Scholar
  • 13 Mehta G. Mohal N. Tetrahedron Lett.  2001,  42:  4227 
    CrossrefGoogle Scholar
  • 14 Prabhu KR. Deven MN. Chandrasekaran S. Synlett  2002,  1762 ; and references therein
    Article in Thieme ConnectGoogle Scholar
  • 15 Habay SA. Schafmeister CE. Org. Lett.  2004,  6:  3369 
    CrossrefGoogle Scholar
  • 16a Kaneko M. J. Synth. Org. Chem., Jpn.  1991,  49:  989 
    Google Scholar
  • 16b Boehme RE. Borthwick AD. Wyatt PG. Annu. Rep. Med. Chem.  1994,  29:  145 
    Google Scholar
  • 16c Cabib E. Antimicrob. Agents Chemother.  1991,  35:  170 
    Google Scholar
  • 16d Gaughran JP. Lai MH. Kirsch DR. Silverman SJ. J. Bacteriol.  1994,  176:  5857 
    Google Scholar
  • 16e Aoki Y. Kondoh M. Nakamura M. Fujii T. Yamazaki T. Shimada H. Arisawa M. J. Antibiot.  1994,  47:  909 ; and references therein
    Google Scholar
  • 17a Barrett AGM. Lebold SA. J. Org. Chem.  1990,  55:  3853 
    Google Scholar
  • 17b Barrett AGM. Lebold SA. J. Org. Chem.  1990,  55:  5818 
    Google Scholar
  • 17c Auberson Y. Vogel P. Tetrahedron  1990,  46:  7019 
    Google Scholar
  • 17d Barrett AG. Lebold SA. J. Org. Chem.  1991,  56:  4875 
    Google Scholar
  • 17e Koizumi K. Kitada Y. Yokoyama C. Ogawa S. J. Chem. Soc., Chem. Commun.  1994,  111 
    Google Scholar
  • 17f Dondoni A. Junquera F. Merchan FL. Merino P. Tejero T. Tetrahedron Lett.  1994,  35:  9439 
    Google Scholar
  • 17g Evina CM. Guillerm G. Tetrahedron Lett.  1996,  37:  163 
    Google Scholar
  • 17h Trost BM. Shi Z. J. Am. Chem. Soc.  1996,  118:  3037 
    Google Scholar
  • 17i Knapp S. Chem. Rev.  1995,  95:  1859 
    Google Scholar
  • 18 Kim C. Hoang R. Theodorakis A. Org. Lett.  1999,  1:  1295 
    CrossrefGoogle Scholar
  • 19a Bhaket P. Stuaffer CS. Dutta A. J. Org. Chem.  2004,  69:  8594 
    Google Scholar
  • 19b Bhaket P. Stuaffer CS. Fothergill AW. Rinaldi MG. Dutta A. J. Org. Chem.  2007,  72:  9991 
    Google Scholar
  • 20 Stuaffer CS. Dutta A. J. Org. Chem.  2008,  73:  4166 
    CrossrefGoogle Scholar
  • For reviews, see:
  • 22a Reissig HU. Top. Curr. Chem.  1988,  144:  73 
    Google Scholar
  • 22b Reissig HU. Zimmer R. Chem. Rev.  2003,  103:  1151 
    Google Scholar
  • 22c Yu M. Pagenkopf BL. Tetrahedron  2005,  61:  321 
    Google Scholar
10

Addition of further equivalence of the reagents did not result in any noticeable increase in the yield. The use of excess NIS in the presence of stoichiometric amount of nucleobase was not effective as the reaction was found to be incomplete even after 48 h.

11

CCDC 706702 contains the supplementary crystallographic data for the azide 5.

21

General Procedure for the NIS-Mediated Ring Opening of Cyclopropyl Carboxylates; Synthesis of Iodide 4: To a solution of cyclopropyl carboxylate 2 (0.488 g, 1 mmol) in CH2Cl2 (10 mL), freshly prepared TMS-activated thymine 3 (0.675 g, 2.5 mmol) and NIS (0.562 g, 2.5 mmol) were added under an argon atmosphere at r.t. (25 ˚C). After 48 h the reaction mixture was diluted with CHCl3 (10 mL) and then neutralized with dilute Na2S2O3 solution. Insoluble material was removed by filtration. The organic layer was separated and dried over anhyd Na2SO4.The filtrate was concentrated and the crude product was purified by flash chromatography on silica gel (230-400 mesh) using 40% EtOAc-PE, which gave the corresponding iodide 4 as a gummy solid (0.606 g, 82%).
Compound 4: R f (EtOAc-PE, 2:3) 0.35; [α]D +31.0 (c = 2, CHCl3). IR (neat): 3214, 3064, 3032, 1721, 1714, 1694, 1454, 1368, 1267, 1027, 736, 698 cm-¹. ¹H NMR (400 MHz, CDCl3): δ = 9.05 (s, 1 H), 7.10-7.34 (m, 18 H), 5.97 (d, J = 9.9 Hz, 1 H), 5.00 (d, AB type, J = 10.5 Hz, 1 H), 4.74 (d, AB type, J = 10.5, 1 H), 4.31 (d, AB type, J = 10.2 Hz, 1 H), 4.46-4.63 (m, 3 H), 3.98 (q, J = 7.8 Hz, 2 H), 3.81 (dd, J 1 = 3.6 Hz, J 2 = 11.1 Hz, 1 H), 3.62-3.71 (m, 2 H), 3.84 (s, 3 H), 1.94 (s, 3 H). ¹³C NMR (100 MHz, CDCl3): δ = 167.2, 163.1, 150.2, 137.9, 137.7, 137.4, 134.9, 128.4, 127.7, 127.5, 112.3, 82.0, 78.9, 77.4, 74.7, 74.6, 73.4, 68.3, 53.6, 48.8, 23.3, 12.5. HRMS: m/z [M + Na] calcd for C35H37IN2O8: 763.1492; found: 763.1559.
General Procedure for the Preparation of Azides; Synthesis of Azide 5: To a stirred solution of iodide 4 (0.236 g, 0.31 mmol) in anhyd DMF (2 mL) was added sodium azide (0.040 g, 0.62 mmol) and the reaction was stirred for 24 h at r.t. (25 ˚C). Most of the DMF was removed under vacuum followed by dilution with CHCl3 (10 mL), which was washed with H2O. The organic layer was separated and dried over anhyd Na2SO4. The filtrate was concentrated and the crude product was purified by flash chromatography on silica gel (230-400 mesh) using 40% EtOAc-PE to obtain the corresponding azide 5 as a pale yellow solid (0.200 g, 96%).
Compound 5: mp 182 ˚C; R f (EtOAc-PE, 2:3) 0.3; [α]D +42.22 (c = 1.8, CHCl3). IR (neat): 2114, 1744, 1713, 1693, 1496, 1265, 737, 699 cm-¹. ¹H NMR (400 MHz, CDCl3):
δ = 8.45 (s, 1 H), 7.22-7.37 (m, 15 H), 6.99 (s, 1 H), 5.77 (d, J = 7.1 Hz, 1 H), 5.00 (d, J = 11.6 Hz, 1 H), 4.32 (d, J = 10.4 Hz, 1 H), 4.66 (dd, J = 4.8 Hz, J 2 = 17.2 Hz, 2 H), 4.57 (d, J = 12.4 Hz, 1 H), 4.49 (d, J = 12.4 Hz, 1 H), 4.39 (d, J = 1.8 Hz, 1 H), 3.83-3.72 (m, 3 H), 3.64-3.66 (m, 1 H), 3.55 (m, 4 H), 2.51 (br s, 1 H), 1.91 (s, 3 H). ¹³C NMR (100 MHz, CDCl3): δ = 169.4, 163.0, 149.4, 137.6, 137.5, 137.4, 128.6, 128.5, 128.4, 128.3, 128.1, 127.9, 110.8, 79.0, 78.4, 77.3, 75.2, 74.8, 73.4, 68.0, 57.9, 52.7, 47.3, 22.5. HRMS: m/z [M + Na] calcd for C35H37N5O8: 678.2540; found: 678.2554.
General Procedure for the Reduction of Azides Using Zn; Synthesis of Amino Acid Nucleoside 6: To a stirred solution of azide 5 (0.105 g, 0.16 mmol) in AcOH-THF (1:1, 5 mL) was added zinc (0.0009 g, 10 mmol%) and the reaction was stirred for 3 h at r.t. (25 ˚C). After the disappearance of the starting material (by TLC), Zn was removed by filtration and the filtrate was diluted with EtOAc (15 mL). The organic layer was thoroughly washed with NaHCO3 solution. It was separated and dried over anhyd Na2SO4. The filtrate was concentrated and the crude product was purified by flash chromatography on silica gel (230-400 mesh) using 20% MeOH-CHCl3 to obtain the corresponding C-2 amino acid nucleoside 6 as a colorless gummy solid (0.080 g, 80%).
Compound 6: R f (MeOH-CHCl3, 4:1) 0.35; [α]D +12 (c = 2, CHCl3). IR neat): 3584, 3064, 3031, 2953, 2919, 1739, 1733, 1694, 1455, 1368, 1267, 1155, 1111, 736, 698, 666 cm-¹. ¹H NMR (400 MHz, CDCl3): δ = 8.92 (br s, 1 H), 7.21-7.33 (m, 15 H), 7.06 (s, 1 H), 5.77 (d, J = 10.4 Hz, 1 H), 4.99 (d, J = 11.6 Hz, 1 H), 4.86 (d, J = 11.2 Hz, 1 H), 4.73 (d, J = 11.6 Hz, 1 H), 4.65 (d, J = 11.2 Hz, 1 H), 4.50-4.60 (m, 3 H), 4.10-4.04 (m, 1 H), 3.61-3.80 (m, 6 H), 3.46 (s, 3 H), 2.41 (m, 1 H), 1.93 (s, 3 H). ¹³C NMR (100 MHz, CDCl3): δ = 176.0, 163.8, 150.7, 138.5, 138.3, 136.0, 129.0, 128.9, 128.4, 128.3, 128.2, 111.6, 80.0, 79.5, 75.7, 75.3, 73.8, 68.8, 52.5, 51.0, 49.9, 30.8, 12.9. HRMS: m/z [M + Na] calcd for C35H39N3O8: 652.2635; found: 652.2662.
General Procedure for the Reduction of Azide 10 Using Pd/C: A suspension of 10% Pd/C (0.040 g) and azide 10 (0.040 g, 0.06 mmol) in MeOH (2 mL) under hydrogen atmosphere was stirred for 12 h at ambient temperature (25 ˚C). The catalyst was filtered and washed with MeOH (20 mL). The filtrate was concentrated and the crude product was purified by flash column chromatography (10% CHCl3-MeOH) to get the corresponding amino triol 27 as a gummy solid (0.017 g, 82%).
Compound 27: R f (MeOH-CHCl3, 1:9) 0.2; [α]D +6.5 (c = 2, DMF). IR (neat): 3417, 1659, 1651, 1644, 1049, 1026, 1004, 826, 764 cm-¹. ¹H NMR (400 MHz, DMSO): δ = 10.32 (s, 1 H), 7.50 (d, J = 8.1 Hz, 1 H), 5.60 (d, J = 8.0 Hz, 1 H), 5.56 (d, J = 10.0 Hz, 1 H), 4.45 (t, J = 6.0 Hz, 1 H), 3.73 (d, J = 12.0 Hz, 1 H), 3.53-3.66 (m, 5 H), 3.20-3.35 (m, 2 H), 1.89-2.13 (m, 5 H). ¹³C NMR (100 MHz, DMSO): δ = 177.2, 163.8, 151.5, 141.9, 103.0, 81.1, 79.9, 72.0, 61.9, 52.6, 51.1, 50.1, 21.6. HRMS: m/z [M + Na] calcd for C13H19N3O8: 368.1070; found: 368.1065.